Exploring metabolic pathway disruption in the subchronic phencyclidine model of schizophrenia with the Generalized Singular Value Decomposition

Table 3 Metabolite identities and their relevant KEGG pathways in the bottom cluster of Figure 11

Formula	Metabolite	Metaboite KEGG ID	KEGG Pathways	P-value	Ratio
C ₅ H ₄ N ₄ O ₂	Xanthine	c00385	ko00230	0.339	0.508
C ₁₀ H ₁₆ N ₂ O ₇	Gamma- glutamylglutamic acid	NA	NA	0.143	0.54
C ₁₄ H ₂₆ O ₂	Myristoleic acid	c08322	NA	0.689	0.623
C ₅ H ₄ N ₄ O	Hypoxanthine	c00262	ko00230	0.115	0.569
C ₁₇ H ₃₇ NO ₂	Heptadecasphinganine	NA	NA	0.733	0.769
C ₁₀ H ₁₃ N ₄ O ₈ P	Inosine monophosphate	c00130	ko00230	0.461	0.73
C ₁₀ H ₁₇ N ₃ O ₆	Peptide fragment (Arg-Arg-Gln)	NA	NA	0.775	1.183
C ₆ H ₁₅ NO ₃	Triethanolamine	c06771	ko00564	0.691	1.207
C ₉ H ₁₄ N ₄ O ₃	Carnosine	c00386	ko00340, ko00410	0.872	1.128
C ₁₀ H ₁₂ N ₄ O ₅	Inosine	c00294	ko00230	0.090	0.6
C ₁₅ H ₁₂ O ₅	Narigenin	c00509	NA	0.196	0.862
C ₁₀ H ₁₇ N ₃ O ₆	gamma Glutamylglutamine	NA	NA	0.007	0.673
C ₂₆ H ₄₂ N ₇ O ₂₀ P ₃ S	2-Hydroxyglutaryl-CoA	c03058	map00650	0.179	0.715
C ₃₁ H ₅₄ N ₇ O ₁₇ P ₃ S	Decanoyl-CoA	c05274	ko00071	0.410	1.312
C ₂₅ H ₄₄ NO ₇ P	2- Aminoethylphosphocholate	c05683	ko00440	0.243	0.662
C ₂₂ H ₂₆ O ₆	Eudesmin	NA	NA	0.084	0.493
C ₃ H ₇ NO ₂ S	L-Cysteine	c00097	ko00260, ko00270, ko00430, ko00480, ko00730, ko00770, map00920	0.012	0.445
C₃H₇O₆P )	Glycerone phosphate	c00111	ko00010, ko00051, ko00052, ko00561, ko00562, ko00564, ko00620	0.063	0.381

Table 3 concerns the bottom cluster of metabolites identified by the GSVD algorithm that are present in the PFC of control animals but not PCP-treated animals. The molecular formula, tentative molecular identity, its KEGG compound identity and the KEGG metabolic pathways in which a given metabolite is involved are shown. The identity of each KEGG pathway ID is shown in Table 5. The p -values and ratio change reported for each metabolite in this table are those calculated by SIEVE analysis. Those metabolites found to be significantly different between the two groups by analysis are highlighted in bold. While SIEVE analysis fails to attribute significance (p < 0.05) to PCP-induced alterations in the overt concentration of many metabolites for many metabolites in this cluster, the PCP/Control ratio suggests that the levels of many of these metabolites are markedly altered by PCP-treatment. GSVD analysis reveals that the relationship between the levels of these metabolites in this cluster are significantly altered by PCP-treatment (p < 0.001) highlighting specific metabolic pathways that may be disrupted in the PFC of PCP-treated animals. There appears to be an overabundance of Purine (4 metabolites [ko00230]) and Glycerophospholipid (2 metabolites [ko00564]) in the bottom cluster.

ISSN: 1752-0509